Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor

National Medical Journal of China

Volumn 86, Issue 34, 2006, Pages 2413-2416

  Fu, Yun Bi ^a   Sun, Qi Xin ^b   Meng, Fan Yi ^b   Xie, Jun ^b   Zhou, Guang Biao ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Apoptosis; Bortezomib; HL60 cell; Leukemia, myeloid

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE 3; CASPASE 9; HOE 33342; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME INHIBITOR; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL NUCLEUS; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MITOSIS INHIBITION; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CASPASE 3; CASPASES; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES;

EID: 37849186572     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Dai Y, Rahmani M, Pei XY, et al. Bortezomib and avopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood, 2004, 104: 509-518.
2. Richardson PG, Hideshima T, Mitsiades C, et al. Proteasome inhibition in hematologic malignancies. Ann Med, 2004, 36: 304-314.
3. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor Bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol, 2005, 23: 676-684.
4. An WG, Hwang SG, Trepel JB, et al. Protease inhibitorinduced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia, 2000, 14: 1276-1283.
5. Zhang GS, Tu CQ, Zhang GY, et al. Indomethacin induces apoptosis and inhibits proliferation in chronic myelogenous leukemia cells. Leukemia Res, 2000, 24: 385-392.
6. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res, 1999,59:2615-2622.
7. Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res, 1999, 5: 2638-2645.
8. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res, 2001, 7: 1419-1428.
9. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res, 2002, 62: 1083-1086.
10. Chinese source. 2005,85:2085-2088.
11. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochrondria blocked. Science, 1997, 275: 1129-1132.
12. Srivastava RK, Sollott SJ, Khan L, et al. Bcl-2 and Bc1-X (L) block thapsigargin-induced nitric oxide generation, c-Jun NH (2)-terminal kinase activity, and apoptosis. Mol Cell Biol, 1999, 19: 5659-5674.
13. Kharbanda S, Saxena S, Yoshida K, et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x (L) in response to DNA damage. J Biol Chem, 1999,275:322-327.
14. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood,2003,101:1530-1534.
15. 2-M phase Arrest and Apoptosis. Mol Cancer Ther, 2002, 1: 841-849.
16. Zhang XM, Lin H, Chen C, et al. Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces BcI-2 cleavage in human M-07e leukaemic cells. Biochem J, 1999, 340:127-133.
17. Duechler M, Shehata M, Schwarzmeier JD, et al. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia, 2005, 19: 260-267.
18. Chunrong Y, Mohamed R, Daniel C, et al. The proteasome inhibitor Bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl + cells sensitive and resistant to STI571. Blood, 2003, 102: 3765-3773.
19. Bei Z, Georgios VG, Yang L, et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res, 2004, 10: 3207-3215.